A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 52 Week Study to Evaluate the Efficacy and Safety of LY3454738 in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Latest Information Update: 06 Jun 2025
At a glance
- Drugs Ucenprubart (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
Most Recent Events
- 31 May 2025 Status changed from active, no longer recruiting to discontinued, due to efficacy/effectiveness reasons.
- 17 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 24 Jul 2024 Planned End Date changed from 1 Jul 2025 to 1 Mar 2026.